Malignant Solid Neoplasm Clinical Trial
Official title:
Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations: Development and Validation of a Personalized Clinical Trial Educational Platform to Boost Participation Among Underserved Cancer Patients
Verified date | October 2023 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial investigates the challenges, behavioral patterns, and preferences towards participation in clinical trials in minority patient populations in order to develop a personalized clinical trial educational platform to increase participation in clinical trials among underserved cancer patients. Learning more about patients' understanding of clinical trials may help identify barriers that limit patient's participation. Information gathered from this trial will be used to develop educational materials that may aid minority patients in overcoming barriers to participating in clinical trials. A personalized clinical trial educational platform may help increase participation in clinical trials among minority populations.
Status | Recruiting |
Enrollment | 3250 |
Est. completion date | October 15, 2024 |
Est. primary completion date | October 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - PART I: Subjects must be adults with age >= 18 years at the time of study entry - PART I: Subjects with any cancer diagnosis may be included - PART I: Subjects must be identified as new patients to hematology oncology at the treating site - PART I: Subjects must be willing to provide informed consent for the study - PART II: Subjects must be adults with age >= 18 years at the time of study entry - PART II: Subjects with any cancer diagnosis may be included - PART II: Subjects must be identified as new patients to hematology oncology at the treating site - PART II: Subjects must be willing to provide informed consent for the study Exclusion Criteria: - PART I: Patients reported to have an estimated life-expectancy of < 6 months, as assessed by their clinician - PART I: Patients not willing to complete the Clinical Trials Study survey - PART II: Patients reported to have an estimated life-expectancy of < 6 months, as assessed by their clinician - PART II: Patients not willing to complete the education intervention or continued follow up for at least 2 years |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Florida | Jacksonville | Florida |
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
United States | Mayo Clinic in Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Documentation of patient preferences, understanding, and attitudes regarding clinical trials (part I) | Overall percentages of the individual categories for each item of the survey will be summarized across all individuals. Any continuous items collected will be summarized using Means and/or medians depending on the distribution of the data. Any categorical items will be potentially compared between groups using Chi-square tests. Continuous measures maybe compared using analysis of variance. Most of this analysis will be exploratory though and viewed as hypothesis generating. | Baseline | |
Primary | Comparison of patient attitudes regarding clinical trials among cancer patients belonging to different racial/ethnic groups (part I) | Overall percentages of the individual categories for each item of the survey will be summarized across all individuals. Any continuous items collected will be summarized using Means and/or medians depending on the distribution of the data. Any categorical items will be potentially compared between groups using Chi-square tests. Continuous measures maybe compared using analysis of variance. Most of this analysis will be exploratory though and viewed as hypothesis generating. | Baseline | |
Primary | Knowledge score (part II) | Linear regression to compare knowledge score at baseline in underserved groups with the rest of the cancer patients in the study with adjustment for relevant covariates. We will obtain an estimate of the difference in mean scores along with a 95% confidence interval (CI). | Baseline | |
Primary | Change in knowledge score (part II) | Linear regression to compare change in knowledge score in patients enrolled in the educational intervention versus in the comparator arm. We will adjust for baseline score and obtain an estimated of the difference in mean score change along with a 95% CI. | Baseline up to 6 and 12 months | |
Primary | Patient enrollment in a clinical trial | The binary outcome of whether or not each patient is enrolled in a trial or not, focusing on the underserved patients. A predetermined randomization algorithm/schedule will be utilized. Logistic regression will be used to compare the proportion of patients enrolled in a trial in each of the two study arms. Adjustments will be made for baseline covariates known to be associated with trial participation. A likelihood ratio test will be conducted of the null hypothesis of no difference in proportions in the two groups. The associated odds ratio will be estimated along with a 95% CI. Comparisons will also be made with the non-underserved patients in which the proportion enrolling in trials is expected to be much higher, with or without the intervention. | Up to 24 months | |
Secondary | Association of baseline patient characteristics (socioeconomic status, level of education, social support, among others) with the patient's preferences and understanding regarding clinical trials (part I) | Will be obtained from the Epic electronic medical record and from the baseline survey. Overall percentages of the individual categories for each item of the survey will be summarized across all individuals. Any continuous items collected will be summarized using Means and/or medians depending on the distribution of the data. Any categorical items will be potentially compared between groups using Chi-square tests. Continuous measures maybe compared using analysis of variance. Most of this analysis will be exploratory though and viewed as hypothesis generating. | Baseline | |
Secondary | Association of disease state (newly diagnosed versus previously treated) with patients understanding and behavior towards clinical trial participation (part I) | Overall percentages of the individual categories for each item of the survey will be summarized across all individuals. Any continuous items collected will be summarized using Means and/or medians depending on the distribution of the data. Any categorical items will be potentially compared between groups using Chi-square tests. Continuous measures maybe compared using analysis of variance. Most of this analysis will be exploratory though and viewed as hypothesis generating. | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030427 -
Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT05660421 -
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
|
Phase 2 | |
Suspended |
NCT04060849 -
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
|
Phase 1 | |
Recruiting |
NCT06192875 -
A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
|
||
Completed |
NCT04122118 -
Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor
|
N/A | |
Active, not recruiting |
NCT04940299 -
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03168737 -
18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
|
Phase 1 | |
Active, not recruiting |
NCT06062901 -
An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT02444741 -
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT04081298 -
eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04555837 -
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04983901 -
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
|
Phase 2 | |
Active, not recruiting |
NCT04602026 -
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
|
N/A | |
Recruiting |
NCT04871542 -
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
|
||
Active, not recruiting |
NCT04592250 -
Financial Toxicity in Cancer Patients
|
||
Recruiting |
NCT05112614 -
Role of Gut Microbiome in Cancer Therapy
|
||
Active, not recruiting |
NCT04296305 -
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
|
Phase 4 | |
Recruiting |
NCT05873608 -
Communication Issues in Patient and Provider Discussions of Immunotherapy
|
N/A | |
Recruiting |
NCT02464696 -
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
|
N/A |